drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular immunotherapy (CAR-T)
drug_description
Allogeneic T cells from a new donor engineered to express an anti-CD7 chimeric antigen receptor; CAR engagement drives cytotoxic killing of CD7+ malignant T cells through TCR-like signaling, perforin/granzyme release, and cytokine secretion. Expected on-target depletion of normal CD7+ T cells and some NK cells, leading to T-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived T cells are engineered to express an anti-CD7 chimeric antigen receptor. Upon binding CD7 on malignant T cells, the CAR triggers TCR-like signaling that activates cytotoxic effector functions, including perforin/granzyme-mediated killing and cytokine secretion. On-target effects also deplete normal CD7+ T cells and some NK cells, leading to T-cell aplasia.
drug_name
New donor-derived CD7 CAR T-cell
nct_id_drug_ref
NCT06316427